Generics - Anti-Arthritics/Rheumatics, Pharmaceutical


Popular Filters

US FDA accepts Pennsaid 2% NDA for review


The US Food and Drug Administration has accepted for filing US drugmaker Mallinckrodt's (NYSE: MNK) New…

Anti-Arthritics/RheumaticsGenericsMallinckrodtNorth AmericaNuvo ResearchPennsaidPharmaceuticalRegulation

Generics triple-therapy just as effective as brand-name Enbrel, new study shows


Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in…


USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015


Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

News briefs from Sanofi, EpiCept/Meda, Horizon/Grunenthal and Watson


French drug major Sanofi (Euronext: SAN) and the Joslin Diabetes Center, a teaching and research affiliate…

AllerganAnti-Arthritics/RheumaticsCepleneDiabetesDuexisEpiCeptGenericsGenito-urinaryGrunenthalHorizon PharmaLicensingMedaOncologyPatentsPharmaceuticalResearchSanctura XRSanofiWatson Pharmaceuticals

Back to top